| 注册
首页|期刊导航|中国临床药理学杂志|阿立哌唑与利培酮治疗精神分裂症伴代谢综合征的临床研究

阿立哌唑与利培酮治疗精神分裂症伴代谢综合征的临床研究

陈海峰 孔令军 曹波 李多聪

中国临床药理学杂志2024,Vol.40Issue(8):1126-1130,5.
中国临床药理学杂志2024,Vol.40Issue(8):1126-1130,5.DOI:10.13699/j.cnki.1001-6821.2024.08.008

阿立哌唑与利培酮治疗精神分裂症伴代谢综合征的临床研究

Clinical trial of aripiprazole and risperidone in patients with schizophrenia and metabolic syndrome

陈海峰 1孔令军 1曹波 1李多聪1

作者信息

  • 1. 吉安市第三人民医院精神科,江西 吉安 343000
  • 折叠

摘要

Abstract

Objective To compare the clinical effect of aripiprazole and risperidone in patients with schizophrenia and metabolic syndrome.Methods A retrospective analysis was performed on the case data of schizophrenia and metabolic syndrome.According to different treatment methods,they were divided into risperidone group(oral risperidone,2 mg once,twice a day)and aripiprazole group(oral aripiprazole,5 mg once,once a day).All were treated for 24 weeks and given lifestyle intervention.The clinical effect,scores of positive and negative symptom scale(PANSS),metabolic syndrome-related indexes[systolic blood pressure(SBP),diastolic blood pressure(DBP),body mass index(BMI),fasting blood glucose(FPG),triglyceride(TG)],cognitive function[MATRICS consensus cognitive battery(MCCB)],levels of serum brain-derived neurotrophic factor(BDNF),tyrosine kinase receptor B(TrkB)and glial cell line-derived neurotrophic factor(GDNF)were compared between the two groups.The adverse drug reactions were statistically analyzed in two groups.Results There were 60 cases in risperidone group and 60 cases in aripiprazole group.The total response rates of aripiprazole group and risperidone group were 91.67%and 76.67%,with significant difference(P<0.05).After treatment,scores of positive symptoms in PANSS in aripiprazole group and risperidone group were(10.04±1.55)and(11.52±1.62)points;negative symptom scores were(12.74±2.38)and(14.38±2.25)points;general psychopathology scores were(16.53±4.39)and(19.76±4.10)points;total scores of PANSS were(39.31±6.25)and(45.66±6.71)points;total scores of MCCB were(43.61±8.50)and(40.55±8.16)points;BMI were(24.05±2.52)and(25.73±2.86)kg·m-2;SBP were(123.61±7.64)and(128.75±8.59)mmHg;FPG were(5.69±0.60)and(6.38±0.62)mmol·L-1;TG levels were(1.76±0.20)and(2.01±0.22)mmol·L-1;levels of serum BDNF were(32.41±5.81)and(28.65±4.87)pg·mL-1;TrkB levels were(43.88±5.92)and(41.73±5.63)ng·mL-1;GDNF levels were(587.47±36.12)and(468.23±35.68)pg·mL-1,the differences between the two groups were all statistically significant(all P<0.05).There was no significant difference in the incidence of adverse drug reactions between aripiprazole group and risperidone group(15.00%vs.6.67%,P>0.05).Conclusion Compared with risperidone,clinical effect of aripiprazole is better in patients with schizophrenia and metabolic syndrome,which has fewer effects on body weight,blood pressure and glycolipid metabolism,and it may improve cognitive function by increasing levels of serum BDNF,TrkB and GDNF.

关键词

阿立哌唑/利培酮/精神分裂症/代谢综合征/糖脂代谢/认知功能

Key words

aripiprazole/risperidone/schizophrenia/metabolic syndrome/glycolipid metabolism/cognitive function

分类

医药卫生

引用本文复制引用

陈海峰,孔令军,曹波,李多聪..阿立哌唑与利培酮治疗精神分裂症伴代谢综合征的临床研究[J].中国临床药理学杂志,2024,40(8):1126-1130,5.

中国临床药理学杂志

OA北大核心CSTPCD

1001-6821

访问量0
|
下载量0
段落导航相关论文